Healthy myeloid-derived suppressor cells express the surface ectoenzyme Vanin-2 (VNN2).
Amidohydrolases
/ metabolism
Biomarkers
/ analysis
CD8-Positive T-Lymphocytes
/ immunology
Cell Adhesion Molecules
/ metabolism
Cell Proliferation
/ physiology
GPI-Linked Proteins
/ metabolism
Glioma
/ diagnosis
HLA-DR Antigens
/ metabolism
Humans
Lipopolysaccharide Receptors
/ metabolism
Lymphocyte Activation
/ immunology
Membrane Proteins
/ metabolism
Monocytes
/ immunology
Myeloid-Derived Suppressor Cells
/ immunology
Neoplasm Grading
Protein Array Analysis
Sialic Acid Binding Ig-like Lectin 3
/ metabolism
GPI-80
Immunosuppression
Mo-MDSC
VNN2
Journal
Molecular immunology
ISSN: 1872-9142
Titre abrégé: Mol Immunol
Pays: England
ID NLM: 7905289
Informations de publication
Date de publication:
02 2022
02 2022
Historique:
received:
21
06
2021
revised:
18
11
2021
accepted:
09
12
2021
pubmed:
26
12
2021
medline:
24
2
2022
entrez:
25
12
2021
Statut:
ppublish
Résumé
Study of human monocytic Myeloid-Derived Suppressor cells Mo-MDSC (CD14
Identifiants
pubmed: 34953280
pii: S0161-5890(21)00350-3
doi: 10.1016/j.molimm.2021.12.011
pmc: PMC8800381
mid: NIHMS1766753
pii:
doi:
Substances chimiques
Biomarkers
0
CD14 protein, human
0
CD33 protein, human
0
Cell Adhesion Molecules
0
GPI-Linked Proteins
0
HLA-DR Antigens
0
Lipopolysaccharide Receptors
0
Membrane Proteins
0
Sialic Acid Binding Ig-like Lectin 3
0
Amidohydrolases
EC 3.5.-
VNN2 protein, human
EC 3.5.1.92
Types de publication
Journal Article
Research Support, N.I.H., Extramural
Research Support, Non-U.S. Gov't
Langues
eng
Sous-ensembles de citation
IM
Pagination
1-10Subventions
Organisme : NIAMS NIH HHS
ID : P30 AR039750
Pays : United States
Organisme : NIAMS NIH HHS
ID : P50 AR055508
Pays : United States
Organisme : NIAMS NIH HHS
ID : R01 AR051498
Pays : United States
Organisme : NCI NIH HHS
ID : R21 CA256573
Pays : United States
Informations de copyright
Copyright © 2021 Elsevier Ltd. All rights reserved.
Références
Cell Stem Cell. 2015 Jan 8;16(1):80-7
pubmed: 25465114
J Immunol. 2013 Jul 1;191(1):17-23
pubmed: 23794702
J Invest Dermatol. 2016 Sep;136(9):1801-1810
pubmed: 27236103
Eur J Immunol. 2009 Oct;39(10):2865-76
pubmed: 19637228
Blood. 2011 Aug 25;118(8):2254-65
pubmed: 21734236
Hepatology. 2012 Feb;55(2):343-53
pubmed: 21953144
J Immunol. 1999 Apr 1;162(7):4277-84
pubmed: 10201959
Immunity. 1996 Nov;5(5):391-405
pubmed: 8934567
PLoS One. 2015 Mar 04;10(3):e0119662
pubmed: 25738302
Semin Cancer Biol. 2012 Aug;22(4):282-8
pubmed: 22313876
Cancer Res. 2007 Jan 1;67(1):425; author reply 426
pubmed: 17210725
Cell Death Dis. 2020 Oct 27;11(10):921
pubmed: 33110074
Clin Immunol. 2013 Oct;149(1):111-8
pubmed: 23954573
Mol Med Rep. 2016 Oct;14(4):3935-40
pubmed: 27574042
J Immunol. 2008 Oct 15;181(8):5791-802
pubmed: 18832739
J Immunother Cancer. 2019 Aug 28;7(1):230
pubmed: 31462270
J Immunother Cancer. 2020 Sep;8(2):
pubmed: 32907925
Immunobiology. 2003;207(3):217-21
pubmed: 12777063
J Neurooncol. 2017 Aug;134(1):189-196
pubmed: 28551851
Nat Rev Immunol. 2009 Mar;9(3):162-74
pubmed: 19197294
J Invest Dermatol. 2016 Apr;136(4):798-808
pubmed: 26807516
Gene. 2008 Dec 15;426(1-2):57-64
pubmed: 18805469
Nat Rev Cancer. 2013 Oct;13(10):739-52
pubmed: 24060865
Immunology. 2012 Jun;136(2):176-83
pubmed: 22304731
J Clin Invest. 2021 Mar 15;131(6):
pubmed: 33492309
Methods. 2001 Dec;25(4):402-8
pubmed: 11846609
Nat Immunol. 2018 Feb;19(2):108-119
pubmed: 29348500
J Immunol. 2015 May 1;194(9):4397-412
pubmed: 25825443
J Exp Med. 2005 Oct 3;202(7):931-9
pubmed: 16186186
Cancer J. 2010 Jul-Aug;16(4):348-53
pubmed: 20693846
J Pharmacol Sci. 2013 Sep 20;123(1):1-8
pubmed: 23978960
J Immunol. 2009 Jan 1;182(1):240-9
pubmed: 19109155
BMC Immunol. 2012 Dec 12;13:69
pubmed: 23234398